The anticipation surrounding the 8:30 a.m. Eastern conference call follows a period of aggressive market growth for the company. First Tracks has seen its stock climb nearly 68% year-to-date, reflecting high expectations for its pipeline. Analysts and shareholders are looking for evidence of efficacy and safety in the phase 1 trial data before the company expands its testing of the drug. The scheduled readout represents a critical milestone for the biotech, which is looking to establish a foothold in the competitive landscape of autoimmune therapeutics.
First Tracks Shares Surge Ahead of Celiac Drug Data Reveal
Investors pushed First Tracks Biotherapeutics shares up 15% to $36.71 in premarket trading Friday, betting on the company’s upcoming clinical update. The biotech firm confirmed it will disclose top-line results from the initial cohort of an early-stage study testing ANB033, a potential treatment for celiac disease, during a Monday morning webcast.
Comments (0)
No comments yet. Be the first!